Source: People’s Daily Online-Hainan Channel
People’s Daily Online, Boao, May 24 (Li Xueshan) On May 24, the first “first try” operation for yttrium-90 glass microspheres was performed in China. The successful completion of the Lecheng International Medical Tourism Pilot Zone in Boao, Hainan (referred to as the “Lecheng Pilot Zone”), the smooth implementation of this operation will speed up the process of this product benefiting people in China and fill another cutting-edge technology in the field of liver cancer treatment in China. blank.
The operation was performed by Teng Gaojun, Academician of the Chinese Academy of Sciences and President of Zhongda Hospital Affiliated to Southeast University, Boao Super Hospital, Zhongda Hospital Affiliated to Southeast University and Hainan The medical and nursing team of the Provincial Cancer Hospital jointly completed the project.
Boston Scientific’s TheraSphere yttrium 90 glass microsphere system (hereinafter referred to as “Y90 glass microspheres”) is used for selective internal radiation therapy (SIRT) of liver cancer. It is currently the only one approved by the US FDA in the world. The Y90 microsphere product for the treatment of hepatocellular carcinoma has been widely used abroad for more than 20 years. The treatment principle is to implant high radioactive Y90 glass microspheres inside the tumor to continuously irradiate the tumor tissue. Because the radiation distance of the radiation is limited, it can reduce the damage to the normal liver tissue and adjacent organs. In addition, the product can also “tailor-made” the dose of Y90 glass microspheres for different patients, enabling individualized and precise treatment.
At the press conference held that afternoon, the expert team confirmed that the two cases of yttrium-90 glass microspheres had achieved the expected therapeutic goals.
Teng Gaojun, academician of the Chinese Academy of Sciences and president of Zhongda Hospital affiliated to Southeast University, said: “Y90 glass microspheres have been used in foreign countries. It has been more than 20 years, but it is still blank in China. The successful cooperation between Boston Scientific and the Lecheng Pioneer Zone is of great significance to the development of liver cancer treatment technology in China, and provides a new choice for the precise treatment and multidisciplinary diagnosis and treatment of liver cancer in China. The first cooperation between me and my team in the Lecheng Pioneer Zone, I think this is a new starting point. I believe that with the joint efforts of all parties, our road of integration, development and innovation will definitely become wider and wider. Our cooperation, It will never end.”
“As the only ‘medical special zone’ in China at present, the Lecheng Pioneer District has continuously implemented higher-level opening-up policies, accelerated system integration innovation and industrial integration development in recent years. , has basically achieved the goal of ‘three synchronizations’ of medical technology, equipment, and medicines with the international advanced level, and has become the most important channel for international innovative medical devices to enter China and an important platform for Chinese people to “do not go abroad for serious illnesses.” Lecheng Pioneer Zone Jia Ning, director of the Administration, said that with the successful treatment of the first batch of patients with yttrium-90 glass microspheres, it marks the beginning of clinical application of this technology in mainland China. It is believed that with the later promotion, there will be more patients with liver cancer benefit from it.
“Everyone is gathering firewood and the flame is high. The high-quality development of Lecheng needs the joint promotion of government departments, pharmaceutical companies, hospitals and experts. You are welcome to bring advanced technology, innovative products, and medical care. The team is here. Lecheng Administration will uphold the spirit of the second shopkeeper, take serving the medical institutions, multinational pharmaceutical and device companies, patients, and medical staff in the park as the first task of its work, and strive to achieve win-win cooperation and common development, so as to build a higher level of Health Island, promote the development of the domestic big health industry and make positive contributions to the construction of the Hainan Free Trade Port.” Jia Ning said that the Lecheng Pioneer Zone will continue to optimize the business environment and seek high-quality development of the medical industry with global pharmaceutical and equipment companies. city model”.
As the first medical device enterprise partner in the real-world research field of the Lecheng Pioneer District, Boston Scientific actively explores “first-in-class” and real-world research, and has successively introduced a number of innovative products, becoming the No. The second batch of medical device companies with the most “real world research” pilot products. Its hot steam therapy device and disposable prostate steam therapy device Rezūm, which were approved for marketing in March this year, are the third innovative medical device in the Lecheng Pioneer District that has been approved by the State Drug Administration through the assistance of real-world research data. .
Zhang Jun, President of Boston Scientific Greater China, said: “For more than two years, Boston Scientific has witnessed the rapid progress of the Lecheng Pioneer District from a ‘policy highland’ to a ‘platform highland’. If the previous cooperation It is the 1.0 era, so the successful launch of the Y90 glass microspheres ‘first trial’ project will open the 2.0 era of our cooperation. In the future, we will further implement the multi-party synergy and integration of ‘industry, university, research, medical and government’ to implement more ‘first cases’ ‘, explore more effective innovations, and help the Lecheng Pioneer District to create a world-class window for medical opening.”
For inoperable liver cancer, interventional therapy, immunotherapy and targeted therapy are mainly used in clinical practice. systemic therapy to prolong the patient’s survival as much as possible. As a treatment method with the dual advantages of precise minimally invasive intervention and precise nuclear medicine diagnosis and treatment, Y90 glass microspheres have been proved by a large number of clinical treatments that it has good survival benefits in the treatment of patients with liver cancer at all stages, including being a part of Patients who are eligible for surgical resection can regain the opportunity for radical surgery through downstaging treatment.
The expert who carried out the first operation of the “first trial” operation – Director of Interventional Department of Hainan Cancer Hospital Niu Huimin said: “During the implementation of the first domestic Y90 glass microsphere treatment, our hospital actively played the role of experts. The advantages of the team and advanced diagnosis and treatment equipment, multi-disciplinary cooperation, do a good job of pre-screening, evaluation, surgery and postoperative monitoring, follow-up full-process diagnosis and treatment services, escort Y90 glass microspheres for clinical treatment of patients. In the future, we will continue to cooperate with Boao Supermarket The hospital, multi-district and multi-discipline will join hands to create a ‘Chinese model’ for Y90 microsphere therapy, which will benefit more domestic liver cancer patients.”